Skip to main content

Tweets

Can lowering serum urate also lower CV risk? In >116k patients w/ #gout, achieving SU <360 µmol/L in 12m ↓ 5yr MACE risk (HR 0.89, pooled Δsurvival +1.4%). Greater effect in >65s. Gout management = CV prevention? @RheumNow #EULAR2025 #OP0005 https://t.co/NRAerUBemN
Mrinalini Dey @DrMiniDey ( View Tweet )
7 months 2 weeks ago
STAMP RCT early SEC vs. SoC 120pts Retention 58% vs 30% ACR 20, 50, 70 and MDA: better outcome at Month 3 but no difference at Month 6 Dactylitis no difference Of note here SoC was a tight T2T strategy! @RheumNow #OP0092 #EULAR2025 https://t.co/8zHs5CRFV5
Aurelie Najm @AurelieRheumo ( View Tweet )
7 months 2 weeks ago
What happens in pre-RA when you stop #abatacept after 1 yr Rx At 6 yrs approx 60% on #Placebo V 50% who initially got #ABA Prolonged damped effect of development of #RA NNT for 1 yr is ~10 with a range as low as 6 #EULAR2025 @RheumNow @eular_org Abst#OP0004 https://t.co/1VOEaZ00Ia
Janet Pope @Janetbirdope ( View Tweet )
7 months 2 weeks ago
#EULAR2025 Abstr#OP0075 Interesting that even among #SLE patients, no single definition of “Lupus Under Control” reached at least 50% agreement. Live Poll with clinicians in the room further highlighted the discordant. More works are needed - to help tailor management @RheumNow https://t.co/WzkQkMD23i
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
7 months 2 weeks ago
#EULAR2025 Abstr#OP0032 “Off-the-Shelf” iPSC-derived CAR-T is coming soon! Promising data on 5 #SLE patients in Phase 1. Advantages over autologous/allogenic: -No apheresis -No conditioning chemo -Shorter hospital stays ~3days -Ability to redose in partial responder @RheumNow https://t.co/qimC94pVU1
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
7 months 2 weeks ago
Should we start strong in PsA? In the SPEED RCT (Coates et al), both early TNFi and combo csDMARDs outperformed step-up care in moderate-severe PsA. TNFi showed the most sustained benefit through 48w. Abstract#OP0089 @RheumNow #EULAR2025

Jiha Lee @JihaRheum ( View Tweet )

7 months 2 weeks ago
First FcRn inhibitor in #IIM: In #ALKIVIA, SC efgartigimod PH20 improved TIS vs placebo at 24wks (50.45 vs 35.65, p=0.0004), with faster time to TIS≥20 (30 vs 71.5d) & TIS≥40 (113d vs NE). More major responders too (TIS>60: 34% vs 9.5%). @RheumNow #EULAR2025 #OP0002 https://t.co/75BfbXoVpL
Mrinalini Dey @DrMiniDey ( View Tweet )
7 months 2 weeks ago
Muscle biopsies form 3 treatment-naïve juvenile dermatomyositis (JDM) finds transcriptomic evidence of mitochondrial dysfunction consistently in JDM muscle, independent of interferon-driven inflammation. Treating mitochondrial dysfunction may improve JDM outcomes https://t.co/u5tMhT23si
Dr. John Cush @RheumNow ( View Tweet )
7 months 2 weeks ago
How to patients with rheumatic diseases consume online health information? 78% used internet for health information 50% use it atleast a month 66% found online information superior 41% used social media! 80% using it to find treatment optio ns! @rheumnow #EULAR2025 https://t.co/diMCloFFVF
Bella Mehta @bella_mehta ( View Tweet )
7 months 2 weeks ago
Rheumatologists can’t ignore hypereosinopilic syndrome anymore, not when it borders on our diseases and therapies. Great takeaways on subtypes and therapies from Giacomo Emmi in an elegant talk #EULAR2025 @RheumNow https://t.co/vqZajY0nUp
David Liew @drdavidliew ( View Tweet )
7 months 2 weeks ago
Platelet rich plasma in knee #OA! They asked this to #ChatGPT ... Whatever is out there on the internet will contaminate responses which pts rely on..:( @rheumnow #EULAR2025 https://t.co/stlbhHp3zp
Bella Mehta @bella_mehta ( View Tweet )
7 months 2 weeks ago
Treatment of MAS, or the bête noire in Still's disease, presented at the Plenary session by Peter Nigrovic #Plenary room #EULAR2025 @RheumNow https://t.co/S4SG2VflNg
Nelly ZIADE 🍀 @Nellziade ( View Tweet )
7 months 2 weeks ago
×